Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alzheimer Society of Canada

- PMLiVE

Roche receives FDA breakthrough device designation for Alzheimer’s disease blood test

Around 55 million people globally are living with dementia, which is estimated to rise to 139 million by 2050

- PMLiVE

Study reveals early menopause and higher CVD risk could be linked to cognitive decline

Approximately 733,040 people in Canada are estimated to be living with dementia

- PMLiVE

Two UK clinical trials launched to identify blood tests for dementia diagnosis

The neurodegenerative condition affects more than 944,000 people in the UK

- PMLiVE

Therapy Watch launches new tracker covering Alzheimer’s Disease

The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.

Research Partnership

- PMLiVE

Researchers suggest erectile dysfunction drugs could reduce risk of Alzheimer’s

The study found that men prescribed PDE5Is were 18% less likely to develop the disease

Biogen Idec building

Biogen to discontinue Alzheimer’s drug Aduhelm in favour of Eisai-partnered Leqembi

The post-marketing confirmatory study of the intravenous treatment will now be terminated

- PMLiVE

Researchers identify five rare cases of Alzheimer’s from historic medical treatments

The study found that c-hGH treatment transmitted the amyloid-beta protein, a hallmark of AD

- PMLiVE

UK government announces nearly £50m to expand dementia research sites

The funding will be used to enable more people to take part in clinical trials for dementia

- PMLiVE

Study shows blood test could be as accurate as lumbar punctures for detecting Alzheimer’s

ALZpath successfully detected levels of a form of the hallmark tau protein in the blood

- PMLiVE

Study suggests hearing aids could prevent onset and progression of dementia

People with severe hearing loss had an increased risk of up to 20% of developing dementia

- PMLiVE

Nanoparticle-delivered RNA could offer potential therapy for neuroinflammation

The study demonstrated a new way to deliver RNA to the brain's immune cells

- PMLiVE

Study identifies new amyloid-forming protein linked to early-onset dementia

The TAF15 protein is a new potential therapeutic for frontotemporal dementia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links